HomeAI · summaries
Storia in 5 fonti
FDA Approves At-Home Starter Dose of Alzheimer's Drug
Lecanemab decision marks first time patients can begin treatment with home administration
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s…
- ·
morningstar.com
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
